FDA Releases Guidance on Mixing, Diluting, or Repackaging Biological Products

Summary

The FDA has issued a final guidance outlining the conditions under which it will not take enforcement action against pharmacies, facilities, or physicians preparing certain biological products for subcutaneous immunotherapy, including mixing, diluting, or repackaging outside approved license applications.